Registered title, quoted from ClinicalTrials.gov
Sintilimab Combined With Chemotherapy and Radiotherapy in Patients With Inoperable Pancreatic Cancer
An open trial on pancreatic cancer, registered on ClinicalTrials.gov. Led by Shandong Cancer Hospital and Institute; 0 other hospitals on this site are listed as study sites.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT06050317, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 7
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (7 points)Hide the checklist
18 years to 75 years; sex: all
Registered eligibility fields
Pathological tissue-confirmed unresectable locally advanced pancreatic cancer
Inclusion criterion 2
Patients who have previously received anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or another drug that stimulates or synergistically inhibits T-cell receptors
Exclusion criterion 3
ECOG PS 0-1
Inclusion criterion 1
Blood routine examination: Absolute neutrophil count (ANC) ≥ 1.0 ×109 cells/L, platelets ≥ 75×109 cells/L, hemoglobin ≥ 9.0 g/dl
Inclusion criterion 6
AST<2.5 × ULN(Upper Limit of Normal), ALT<2.5 × ULN,creatinine ≤1.5xULN, total bilirubin < ≤1.5 X ULN.
Inclusion criterion 7
Primary pancreatic cancer or at least one measurable lesion specified by RECIST1.1 standards
Inclusion criterion 4
Women who are pregnant
Exclusion criterion 7
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; other conditions the trial excludes.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06050317, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- ECOG PS 0-1
- Pathological tissue-confirmed unresectable locally advanced pancreatic cancer
- Pancreatic cancer patients who have not received systemic anti-tumor therapy
- Primary pancreatic cancer or at least one measurable lesion specified by RECIST1.1 standards
- A life expectancy of > 3 months
- Blood routine examination: Absolute neutrophil count (ANC) ≥ 1.0 ×109 cells/L, platelets ≥ 75×109 cells/L, hemoglobin ≥ 9.0 g/dl
- AST<2.5 × ULN(Upper Limit of Normal), ALT<2.5 × ULN,creatinine ≤1.5xULN, total bilirubin < ≤1.5 X ULN.
Exclusion Criteria:
- Diagnosed with other malignant diseases other than pancreatic cancer within three years before enrollment
- Patients who are currently participating in interventional clinical research treatment or have received other research drugs or used research devices within four weeks before enrollment
- Patients who have previously received anti-PD-1, anti-PD-L1, or anti-PD-L2 drugs or another drug that stimulates or synergistically inhibits T-cell receptors
- Patients who have received systemic treatment with Chinese patent medicines with anti-tumor indications or drugs with immunomodulatory effects within two weeks before enrollment
- Abnormal results of blood routine examinations and liver and kidney and coagulation tests
- Abnormal function of major organs (14 days before enrollment)
- Women who are pregnant
- Inability of the research subject or authorized legal representative to understand and the willingness to sign a written informed consent document.
Quoted from ClinicalTrials.gov, NCT06050317, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT06050317, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.